INmune Bio Inc. Common stock
INMBINmune Bio Inc. (INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies to treat neurodegenerative diseases, cancer, and infectious diseases. The company's approach involves targeting specific immune pathways to modulate the immune response and improve patient outcomes. INmune Bio aims to advance therapies that leverage the body's immune system to fight various diseases more effectively.
Company News
A peer-reviewed study published in Cytotherapy explores the potential of mesenchymal stromal cell (MSC) therapies, focusing on systemic delivery, local delivery methods, and in vivo persistence of cell treatments.
INmune Bio Inc. will host a conference call on August 7th, 2025 at 4:30pm EDT to discuss Q2 2025 financial results and provide a corporate update, focusing on their clinical-stage inflammation and immunology research.
INmune Bio will host a conference call on June 30, 2025, to present top line data from their Phase 2 MINDFuL trial investigating XProâ„¢ treatment for early Alzheimer's Disease, focusing on patients with mild cognitive impairment and neuroinflammation markers.
Inmune Bio, a biopharmaceutical company, held its annual stockholders meeting, resulting in the re-election of its board of directors and the ratification of its independent auditor for the upcoming fiscal year.
Elevai Labs, a pharmaceutical company, has modified its existing license agreement with INmune Bio. The amendment revises the terms related to the technology transfer fee payable to INmune. The companies have updated the financial details of the agreement, which were not disclosed publicly.
